Fifth Lane Capital’s Agile Therapeutics AGRX Stock Holding History

Fifth Lane Capital’s Portfolio AGRX Stock Details AGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-200	Closed	–	–	239
2022 Q3	$0	Buy	+200	New	+$4.92K	﹤0.01%	322

Other funds holding AGRX

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return

ASN

Advisory Services Network Atlanta, Georgia $7.52B AUM 29.01% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Fifth Lane Capital's AGRX Position: Q4 2022 in Review

Fifth Lane Capital sold out of Agile Therapeutics (AGRX) in Q4 2022, closing a stake of 200 shares.

Fifth Lane Capital first reported a position in AGRX in Q3 2022 and held it in 1 quarter. The position peaked at $0 in Q3 2022. 26 funds tracked by Wall St. Rank hold AGRX as of Q4 2022.

Fifth Lane Capital reported no remaining Agile Therapeutics position as of Q4 2022 after selling out during the quarter.
Fifth Lane Capital sold 200 Agile Therapeutics shares in Q4 2022.
Fifth Lane Capital first reported a position in Agile Therapeutics in Q3 2022 and held it in 1 quarter.
Fifth Lane Capital's Agile Therapeutics position peaked at $0 in Q3 2022.
26 funds tracked by Wall St. Rank held Agile Therapeutics as of Q4 2022.

Based on Fifth Lane Capital's 13F filing for Q4 2022, filed 14 Feb 2023.